EP2576770A1 - Method for culturing adipocytes - Google Patents
Method for culturing adipocytesInfo
- Publication number
- EP2576770A1 EP2576770A1 EP11727787.1A EP11727787A EP2576770A1 EP 2576770 A1 EP2576770 A1 EP 2576770A1 EP 11727787 A EP11727787 A EP 11727787A EP 2576770 A1 EP2576770 A1 EP 2576770A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- adipocytes
- culture
- adipocyte
- mature
- adipose tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000001789 adipocyte Anatomy 0.000 title claims abstract description 131
- 238000000034 method Methods 0.000 title claims abstract description 18
- 238000012258 culturing Methods 0.000 title claims abstract description 8
- 210000000577 adipose tissue Anatomy 0.000 claims abstract description 19
- 239000000017 hydrogel Substances 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 16
- 230000004060 metabolic process Effects 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 7
- 230000003213 activating effect Effects 0.000 claims description 4
- 230000004130 lipolysis Effects 0.000 claims description 4
- 102000000536 PPAR gamma Human genes 0.000 claims description 3
- 108091008767 PPARγ2 Proteins 0.000 claims description 3
- 238000009343 monoculture Methods 0.000 claims description 3
- 238000012136 culture method Methods 0.000 claims 1
- 125000001145 hydrido group Chemical group *[H] 0.000 claims 1
- 239000000758 substrate Substances 0.000 abstract description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
- 239000002609 medium Substances 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 18
- 239000000499 gel Substances 0.000 description 13
- 210000000229 preadipocyte Anatomy 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 229940125396 insulin Drugs 0.000 description 10
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 108010076365 Adiponectin Proteins 0.000 description 8
- 102000011690 Adiponectin Human genes 0.000 description 8
- 206010022489 Insulin Resistance Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000002366 lipolytic effect Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 101001062864 Homo sapiens Fatty acid-binding protein, adipocyte Proteins 0.000 description 7
- 102000016267 Leptin Human genes 0.000 description 7
- 108010092277 Leptin Proteins 0.000 description 7
- 229960003957 dexamethasone Drugs 0.000 description 7
- 229940039781 leptin Drugs 0.000 description 7
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 102000014777 Adipokines Human genes 0.000 description 6
- 108010078606 Adipokines Proteins 0.000 description 6
- 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 description 6
- 239000000478 adipokine Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 5
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000003862 glucocorticoid Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000000760 immunoelectrophoresis Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 3
- 229960003015 rimonabant Drugs 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 102100027211 Albumin Human genes 0.000 description 2
- 102000049320 CD36 Human genes 0.000 description 2
- 108010045374 CD36 Antigens Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000000593 adipose tissue white Anatomy 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000000326 densiometry Methods 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
- 229960004425 sibutramine Drugs 0.000 description 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- YYYARFHFWYKNLF-UHFFFAOYSA-N 4-[(2,4-dimethylphenyl)diazenyl]-3-hydroxynaphthalene-2,7-disulfonic acid Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=C12 YYYARFHFWYKNLF-UHFFFAOYSA-N 0.000 description 1
- 101100170173 Caenorhabditis elegans del-1 gene Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108090000026 Caveolin 1 Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108010067520 RADA16-I Proteins 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108091006300 SLC2A4 Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000015961 delipidation Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000013190 lipid storage Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0653—Adipocytes; Adipose tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
Definitions
- the invention relates to a method of culturing adipocytes, a culture of adipocytes, and its use for the screening of compounds modulating adipocyte metabolism.
- the current drug approaches are mainly aimed at reducing energy intake, for example by limiting the intestinal absorption of lipids (orlistat), or by decreasing the appetite, either by promoting the feeling of satiety (sibutramine), or by decreasing the pleasure associated with food intake (rimonabant).
- mature adipocyte cells in particular characterized by the presence of a single lipid vacuole, which form the white adipose tissue, are particularly fragile and, in fact, these cells generally lose in less than 48 h their metabolic and secretory properties in culture.
- adipocytes such as pre-adipocytes or endothelial cells (Sonda et al., (2008) Endocrinology 149: 4794-4798), or generally using adipocytes.
- the present invention results from the unexpected finding by the inventors that mature adipocytes isolated from adipose tissue could be cultured, in the absence of other cell types, using a three-dimensional culture support and that the adipocytes thus cultured retain for at least 48 hours a phenotype similar to that of freshly isolated mature adipocytes.
- the present invention thus relates to a method of culturing adipocytes, wherein a homogeneous population of mature adipocytes isolated from adipose tissue is cultured on a three-dimensional culture support.
- the present invention also relates to an adipocyte culture, comprising a monoculture of mature adipocytes isolated from adipose tissue in contact with a three-dimensional culture support.
- the invention also relates to the use of an adipocyte culture according to the invention, for the screening of compounds modulating adipocyte metabolism.
- the invention also relates to a method for screening compounds that modulate adipocyte metabolism, in which:
- a compound to be screened is contacted with a culture of adipocytes according to the invention
- the compound is selected if it modifies at least one representative parameter of the adipocyte metabolism.
- mature adipocytes represents differentiated adipocytes.
- the mature adipocytes can be easily identified by those skilled in the art.
- a mature adipocyte according to the invention usually has a single lipid vacuole, a lipolytic activity, in particular inducible by ⁇ -adrenergic agents, such as adrenaline and norepinephrine, as well as an insulin sensitivity, in particular particular defined by insulin-inducible transport, from the extracellular medium to the intracellular medium, glucose and fatty acids, which transport is particularly related to the insulin-dependent translocation, within the plasma membrane of mature adipocytes, GLUT-4 and CD36 carriers respectively.
- the mature adipocytes according to the invention are distinguished in particular from pre-adipocytes, in particular in that the expression of the specific marker of the pre-adipocytes DelK1 / Prefl, well known to those skilled in the art, which can be measured by PCR in time. real, is essentially absent in mature adipocytes according to the invention.
- the mature adipocytes according to the invention are isolated from adipose tissue.
- mature adipocytes according to the invention are especially such that they do not come from the in vitro differentiation of adipocyte precursors, such as pre-adipocytes or stem cells, totipotent, multipotent, or pluripotent.
- the adipose tissue according to the invention can come from any animal species. However, it is preferred that the adipose tissue according to the invention has been removed from one or more human individuals.
- the mature adipocytes can be isolated from adipose tissue by many methods well known to those skilled in the art, taking particular advantage of the low density of mature adipocytes.
- the adipose tissue can be treated with collagenase, then after digestion, be filtered on woven cotton gauze; the filtrate is left to decant in an aqueous medium and a homogeneous population of mature adipocytes according to the invention can be recovered by harvesting the floating cells.
- a homogeneous population of mature adipocytes is especially such that it is substantially free of other cell types, including endothelial cells, or preadipocytes.
- a homogeneous population of mature adipocytes according to the invention comprises less than 10%, more particularly less than 5% of cells other than mature adipocytes, in particular pre-adipocytes.
- the amount of pre-adipocytes in a homogenous population of mature adipocytes can be determined by quantifying the number of cells expressing a specific preadipocyte marker, such as DelK1 / Prefl for example.
- a "mature adipocyte monoculture” is a culture of a homogeneous population of mature adipocytes.
- a homogeneous population of mature adipocytes is said to be "cultured” or “cultured” when it is incubated, that is to say preserved in vitro, under conditions allowing the survival of the cells constituting the population.
- Such conditions as well as suitable culture media are well known to those skilled in the art. These culture media are such that they contain all the elements, in particular nutrients, capable of ensuring the survival of the cells constituting the population for at least 12 hours, preferably at least 24 hours, more preferably at least 48 h.
- the population can be incubated in a DMEM / F12 medium, 1% Penicillin-Streptomycin, 50 nM Insulin, with stirring, at 37 ° C. and in an atmosphere at 5% C0 2 , the medium being regularly renewed.
- the mature adipocyte culture media according to the invention may comprise compounds intended to modulate the metabolic activity of mature adipocytes, such as forskinin and dexamethasone, for example.
- the culture of the mature adipocyte population is preferably carried out for at least 3 h, 6 h, 12 h, 24 h, or 48 h.
- the mature adipocytes are "cultured on a three-dimensional culture support" when the adipocytes are in contact with the support, ie they rest on the support or they adhere to the support.
- the method for culturing adipocytes according to the invention comprises the following steps:
- a "three-dimensional culture support” according to the invention consists of a material, in particular biocompatible, adapted to obtain a three-dimensional cell culture; in other words, the three-dimensional culture support is adapted, in particular, to obtaining several layers of superposed cells.
- a culture support allowing only the culture of a two-dimensional cellular mat, namely a monolayer of cells, is not a three-dimensional culture support according to the invention.
- the three-dimensional culture support according to the invention is a hydrogel. More preferably, the three-dimensional culture support according to the invention is a hydrogel formed from the non-covalent association of peptides comprising from 10 to 30 residues, such as peptides comprising a repetition of the RADA sequence, and in particular a RADARADARADARA-DA sequence. (SEQ ID NO: 11).
- the peptides forming the hydrogel can be modified, for example by the addition of acetyl groups on the N-terminus of the peptides and by the addition of a group -N3 ⁇ 4 at the C-terminus of the peptides.
- the peptides can be represented by the sequence: Ac-RADA-RADARADARADA-CONH 2 .
- the three-dimensional culture carrier according to the invention is the hydrogel PuraMatrix TM (3DM, Inc.).
- the compounds which can be screened according to the invention can be of any type. In particular, they may be compounds from chemical libraries. Moreover, the culture of adipocytes according to the invention can be used to screen compounds activating lipolysis, or compounds activating PPARy2 transcription factor; or compounds that modulate insulin sensitivity.
- lipolysis or lipolytic activity
- insulin sensitivity or activity of the PPAR ⁇ 2 transcription factor
- PPAR ⁇ 2 transcription factor are representative parameters of adipocyte metabolism.
- lipolytic activity can be determined by measuring the amount of glycerol and free fatty acids released by an adipocyte culture according to the invention, in particular by spectrophotometry as described in Lacasa et al. (1991) Endocrinology 128: 747-753.
- the insulin sensitivity of adipocytes can be evaluated from the measurement of glucose transport in the adipocyte as described in Wood et al. (2007) B toc hem. Biophys. Res. Common. 361: 468-473.
- the activity of the transcription factor PPARy2 can be measured by determining the amount of mRNA encoding it in a cell, for example by RT-PCR or by direct measurement of the binding activity at its specific DNA sites, such as is described in particular in Keophiphath et al. (2009) J. Nutr. 139: 2055-2060.
- Figures 1 to 3 respectively represent the level of relative expression (ordinate axis, arbitrary units) measured by real-time PCR of three specific markers of mature adipocytes, namely PPARy2, FABP4 (a fatty acid transporter whose gene is a target of PPARy2), and an adipokine, adiponectin, in mature adipocytes freshly isolated from adipose tissue on the one hand (black bars) and in adipocytes obtained by in vitro differentiation of pre-adipocytes as described in Lacasa et al. Endocrinology 148: 868-877, on the other hand ( white bars).
- FIG. 4 shows a cell lysates immunoelectrophoresis gel prepared from mature adipocytes maintained in culture on the three-dimensional support for 48 hours (3D) and freshly isolated mature adipocytes (J0) then labeled using an antibody directed against the adipocyte marker aP2 / FABP4 and an antibody directed against a positive control (actin).
- Figures 5 and 6 show levels of lipolytic activity (y-axis in arbitrary units) basal and stimulated by forskolin (FK) of mature adipocytes grown (i) in the three-dimensional culture substrate (3D) in the absence (white bars) and in the presence of dexamethasone (Dex) (black bars), and (ii) in monolayers (2D) (shaded bars), depending on the culture time (x axis, in days).
- FK forskolin
- Figures 7 and 8 respectively represent the secreted amounts of leptin and adiponectin (y-axis, in ⁇ g / ml / 24h) by mature adipocytes cultured in the three-dimensional culture support (3D) in the absence (white bars) and in the presence of dexamethasone (Dex) (black bars).
- the experiment presented is representative of a set of three replicated experiments.
- FIG. 9 represents the relative gene expression of adipocyte markers (ordinate axes, arbitrary units) measured by real-time PCR from extracts of freshly isolated mature adipocytes (black bars) and mature adipocytes. maintained for 48 hours in culture in the three-dimensional culture support (white bars).
- Figure 10 shows a cell lysates immunoelectrophoresis gel prepared from mature adipocytes maintained in culture on the three-dimensional support for 48 hours (3D) and freshly isolated mature adipocytes (2D) incubated in the presence of insulin (1 nM) at the indicated times then labeled with an antibody directed against the phosphorylated form of Akt and an antibody directed against a positive control (actin).
- the BDTM Puramatrix TM peptide hydrogel is obtained from BD Biosciences (Two Oak Park, Bedford, MA, USA).
- the primary anti-caveolin-1 (N-20, SC-894) and antiCD36 (1.BB.3414, CS-70642) antibodies used are from Santa Cruz Biotcchnology (Santa Cruz, CA, USA).
- the corresponding Cy3-coupled antibodies are obtained from GE Healthcare (Little Chalfont, UK).
- the mature adipocytes are isolated by collagenase treatment of human adipose tissue.
- the subcutaneous human adipose tissue of young ( ⁇ 45 years old) and non-obese (BMI ⁇ 30) women is cut out of digestion media (DMEM, 2% low fatty acid albumin (A6003, Sigma St Louis, MI, USA). ), 1 mg / ml collagenase A (Roche Diagnostics, Mannheim, Germany) in the proportion of 1 g of tissue per 2 ml of digestion medium in polypropylene tubes The tubes are placed at 37 ° C.
- the medium is filtered on woven cotton gauze
- the mature adipocytes are allowed to settle by flotation for 5 minutes and then washed 3 times with 5 volumes of sucrose 10%
- the sucrose is withdrawn and the mature adipocytes are ready to be incorporated into the Puramatrix TM hydrogel.
- the hydrogel is sonicated for 30 minutes to reduce its viscosity.
- the gel is then diluted V / V with 20% sucrose and then centrifuged for 5 minutes at 1000 g to remove the air bubbles.
- the washed mature adipocytes are rapidly incorporated into this mixture with homogenization by gentle suction with the pipette.
- the adipocytes / gel mixture is then distributed in the proportion of 100 ⁇ l ⁇ per well in 96-well culture plates.
- the incubation medium 150 ⁇ l
- DMI contains 100 nM dexamethasone (Sigma Aldricht, St. Louis, MO, USA) or 100 nM rosiglitazone (Merck, Nottingham, UK).
- the medium is removed and placed for 10 minutes at 70 ° C in order to inactivate the adipocyte enzymes that can interfere with the glycerol assay.
- the glycerol released is assayed spectrophotometrically (Glycerol Assay Kit, R-Biopharm) as described in Lacasa et al. (1991) Endocrinology 128: 747-753.
- the DMI medium is taken 24 hours after the last change of medium.
- adipokines (leptin, adiponectin) is carried out directly on this medium (100 ⁇ l) by the ELISA technique (Duoset, R & D Systems, Minneapolis, MN USA) as described by the manufacturer.
- the DMI medium is rapidly removed from the wells and the gel / adipocyte assembly is homogenized by the lysis buffer in the proportion of 1 ml of lysis buffer / lml of gel / adipocyte assembly.
- the RNAs are then extracted with chloroform delipidation treatment beforehand using the RNeasy extraction kit. (Qiagen, Courtaboeuf, France) as described in Lacasa et al. (2007) Endocrinology 148: 868-877.
- the total (1 ⁇ ") RNAs are then transcribed into cDNA as described in Lacasa et al. (2007) Endocrinology 148: 868-877.
- the list of primers used is shown in Table 1.
- PCR test in real time are performed with 25ng cDNA and forward and reverse primers using the universal PCR mixture Sybergreen (Applied Biosystems, Minneapoîis, MN USA) and measured in a detection device (Applied Biosystems). All values are normalized to RPLPO ribosomal protein expression.
- the gel / adipocyte assembly is deposited in wells of 96-well plates and fixed with 4% paraformaldehyde (PAF) for 1 hour.
- PAF paraformaldehyde
- the cells are permeabilized for 5 minutes at room temperature with 0.1% Triton X-100 in PBS / 3% albumin. Non-specific sites are blocked by PBS / 3% albumin buffer for 4 hours at room temperature, then primary antibodies are added and incubation is continued for 14 hours at 4 ° C.
- the gel / adipocyte assembly is incubated with the secondary antibodies for 4 hours at room temperature in the dark.
- the gel / adipocyte assembly is then washed (1 hour) and fragments of this gel are deposited in mounting medium (Fluomount, Birmingham, Alabama, USA) between blade and lamellae. The slides are examined in fluorescence after 24 hours.
- the gel / adipocyte assembly is rapidly lysed with a volume of lysis buffer (PBS, 2% IGEPAL, 0.2% SDS, 1% sodium desoxycholate) containing a mixture of protease inhibitors and phosphatases (Complete mini and Phosphostop, Roche diagnoses).
- PBS 2% IGEPAL, 0.2% SDS, 1% sodium desoxycholate
- the homogenate is then kept 15 minutes at 4 ° C. and then centrifuged for 10 minutes at 5000 g.
- the cell lysate is then collected and diluted in Laemmli buffer and electrophoresed as described in Lacasa et al. (2007) Endocrinology 148: 868-877.
- Wells containing Phydro gel / fundamentalrivés adipocytes insulin standby times are incubated with incubation medium (150 (DMEM / F 12 and 10 nM Insulin).
- incubation medium 150 (DMEM / F 12 and 10 nM Insulin).
- the plates are then placed in the incubator for 15 to 30 minutes.
- the gel / adipocytes is rapidly lysed with a volume of lysis buffer (PBS, 2% IGEPAL, 0.2% SDS, 1% sodium deoxycholate) containing a mixture of protease inhibitors and phosphatases (Complete mini and Phosphostop, Roche diagnostics)
- the homogenate is then kept 15 minutes at 4 ° C and then centrifuged for 10 minutes at 5000 g.
- the lysate is then collected and diluted in Laemmli buffer and electrophoresed as previously described.
- the membranes are then incubated with the primary antibodies respectively against the phosphorylated form of Akt at Ser 473 (ref G7441 Promega) or against actin (positive control) (MAB1501R, Millipore) at 4 ° C for 14 hours. . After washing, the membranes are incubated with the secondary antibodies (GE Healthcare, Little Chalfont, UK). The signals are detected by chemiluminescence (ECL detection, GE Healthcare) and quantified by densitometry.
- the proportion of contaminating pre-adipocytes present in the mature adipocyte population isolated from adipose tissue used for culture was determined by measuring the real-time PCR expression of the pre-adipocyte specific Del 1 / Prefl marker.
- the mature adipocytes cultured in the three-dimensional support formed by the hydrogel do indeed exhibit a unilocular appearance after immunofluorescence labeling of the CD36 and caveolin-1 membrane proteins, which demonstrates the possibility of detecting membrane adipocyte proteins.
- the adipocyte lysates can be analyzed by immunoelectrophoresis as shown by the detection of the cytosolic adipocyte protein aP2 / FABP4 and actin (FIG. 4),
- the lipolytic activity is measured in terms basalcs conditions and stimulated with 10 ⁇ forskolin in mature adipocytes maintained in the hydrogel for 7 days. This activity is also compared to that of the same freshly isolated cells.
- the results presented in Figures 5 and 6 show that the basal lipophilic activity (Figure 5) and forskolin-stimulated ( Figure 6) is of the same order as that of freshly isolated adipocytes and remains constant for 5-7 days.
- dexamethasone synthetic glucocorticoid
- the secretion of adiponectin (FIG. 7) and leptin (FIG. 8) is measured up to 7 days of maintenance of the mature adipocytes in the hydrogel, in the presence or absence of dexamethasone (synthetic glucocorticoid). Moreover, as shown in FIG. 7, the secretion of leptin decreases during the culture in the absence of dexamethasone whereas this secretion increases in the presence of the glucocorticoid, thus demonstrating that the response to these hormones remains functional in the adipocytes in culture. . The secretion of adiponectin remains constant for 7 days (Figure 8).
- adipoeye genes is compared between freshly isolated mature adipocytes and the same cells maintained for 2 days in hydrogel.
- Figure 9 shows that the expression of adipokines (leptin and adiponectin), the major adipocyte transcription factor PPARy2 and its target genes aP2 / FABP4 and LPL remains constant.
- Adipocytes are a prime target for insulin, a major anabolic hormone.
- insulin stimulates glucose consumption leading to increased synthesis of triglycerides and on the other hand inhibits the degradation of these lipids.
- the Akt enzyme transmits the metabolic effects of insulin which causes its activation by phosphorylation of the 473 seine (Ser 473 Akt).
- Ser 473 Akt phosphorylation of the 473 seine
- Insulin (10 nM) stimulates phosphorylation of Akt in an identical manner in freshly isolated (2D) adipocytes and those maintained for 48 h in the hydrogel (3D) thus indicating a good maintenance of the insulin response. of these cells ( Figure 10).
- the mature adipocytes maintained in a three-dimensional hydrogel culture medium with an incubation medium which can be supplemented with glucocorticoids and thiazolinidinediones, exhibit lipolytic and secretion activity of adipokines (leptin and adiponectin) comparable to those of freshly isolated adipocytes.
- adipokines lactin and adiponectin
- mature adipocytes maintained in the hydrogel retain for at least 7 days the ability to respond to glucocorticoids, hormones crucial for adipocyte metabolism and development (Macfarlane et al (2008) J. Endocrinol 197: 189-204). ).
- this system can be used for the screening of pharmacological compounds having lipolytic activities or adipo-specific transcription factor activation PPAR ⁇ 2, for example.
- mature adipocytes maintained in three-dimensional culture carrier hydrogel according ⁇ invention retain at least 2 days their insulin sensitivity compared to freshly isolated mature adipocytes. This confirms that the culture of adipocyte according ⁇ invention is a model representative of the mature adipocytes in vivo.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
PROCEDE DE CULTURE D'ADIPOCYTES PROCESS FOR CULTIVATION OF ADIPOCYTES
Domaine de l'invention Field of the invention
L'invention concerne un procédé de culture d'adipocytes, une culture d'adipocytes, et son utilisation pour le criblage de composés modulant le métabolisme adipocytaire. The invention relates to a method of culturing adipocytes, a culture of adipocytes, and its use for the screening of compounds modulating adipocyte metabolism.
Arrière-plan technique Technical background
La prévalence de l'obésité, liée à une hypertrophie du tissu adipeux blanc, est en augmentation constante dans la population générale. Ainsi, la proportion des personnes en surpoids ou obèses a progressé de 36,7% à 41,6% entre 1997 et 2003 en France, en outre, la prévalence de l'obésité (définie par un index de masse corporelle (IMC) supérieur 30 kg/m2) y est de 14,5% en 2009. Par ailleurs, l'obésité est un facteur de risque pour de nombreux troubles pathologiques, dont notamment les accidents cardiovasculaires, rendant d'autant plus urgente sa prise en charge thérapeutique. The prevalence of obesity, associated with hypertrophy of white adipose tissue, is steadily increasing in the general population. Thus, the proportion of overweight or obese people increased from 36.7% to 41.6% between 1997 and 2003 in France, in addition, the prevalence of obesity (defined by a higher body mass index (BMI) 30 kg / m 2 ) is 14.5% in 2009. In addition, obesity is a risk factor for many pathological disorders, including cardiovascular events, making it all the more urgent for its therapeutic management. .
Si les principaux axes de lutte contre cette épidémie restent l'amélioration de l'alimentation et l'augmentation de la dépense physique des individus obèses, d'autres approches, notamment chirurgicales et médicamenteuses sont également explorées. If the main axes of fight against this epidemic remain the improvement of the food and the increase of the physical expenditure of the obese individuals, other approaches, in particular surgical and medicinal ones are also explored.
Les approches médicamenteuses actuelles visent principalement à réduire les apports énergétiques, par exemple en limitant l'absorption intestinale de lipides (orlistat), ou en diminuant l'appétit, soit en favorisant la sensation de satiété (sibutramine), soit en diminuant le plaisir associé à la prise alimentaire (rimonabant). The current drug approaches are mainly aimed at reducing energy intake, for example by limiting the intestinal absorption of lipids (orlistat), or by decreasing the appetite, either by promoting the feeling of satiety (sibutramine), or by decreasing the pleasure associated with food intake (rimonabant).
Toutefois, l'efficacité limitée de ces méthodes ou leurs effets secondaires - il a ainsi été rapporté que le rimonabant pouvait provoquer des troubles dépressifs sévères - ont notamment conduit au retrait de la sibutramine et du rimonabant du marché, laissant des options thérapeutiques très limitées et rendant nécessaires l'exploration d'autres voies, permettant par exemple de moduler le métabolisme des cellules adipocytaires pour limiter le stockage des lipides ou au contraire favoriser leur utilisation. Cette dernière voie est cependant rendue difficile d'approche par l'absence de modèles in vitro ou animaux d'étude du métabolisme adipocytaire véritablement représentatifs de la situation in vivo chez l'homme. However, the limited effectiveness of these methods or their side effects - it has been reported that rimonabant could cause severe depressive disorders - have notably led to the withdrawal of sibutramine and rimonabant from the market, leaving very limited therapeutic options and making it necessary to explore other ways, for example to modulate the metabolism of adipocyte cells to limit the storage of lipids or otherwise promote their use. The latter pathway, however, is made difficult to approach by the absence of in vitro models or animal studies of adipocyte metabolism truly representative of the in vivo situation in humans.
En effet, s' agissant des modèles in vitro, les cellules adipocytaires matures, notamment caractérisées par la présence d'une vacuole lipidique unique, qui forment le tissu adipeux blanc, sont particulièrement fragiles et, de fait, ces cellules perdent généralement en moins de 48 h leurs propriétés métaboliques et sécrétoires en culture. Indeed, in the case of in vitro models, mature adipocyte cells, in particular characterized by the presence of a single lipid vacuole, which form the white adipose tissue, are particularly fragile and, in fact, these cells generally lose in less than 48 h their metabolic and secretory properties in culture.
Plusieurs systèmes de culture ont ainsi été proposés pour surmonter ces difficultés. Toutefois, ces cultures comprennent des types cellulaires additionnels en plus des adipocytes, tels que des pré-adipocytes ou des cellules endothéliales (Sonda et al. (2008) Endocrinology 149:4794-4798) ou se font généralement à l'aide d'adipocytes différenciés in vitro à partir de cellules souches (Choi et al, (2010) Tissue Engineering: Part C, Kang et al. (2007) Biomaterials 28:450-458) ou de pré- adipocytes (Daya et al. (2007) Differentiation 75:360-370, WO 2007/1 13591 , Stacey et al. (2009) Tissue Engineering: Part A 15:3389-3399), dont le phénotype est relativement éloigné de celui des adipocytes matures isolés de tissu adipeux (voir les Figures 1 à 3). Several cropping systems have been proposed to overcome these difficulties. However, these cultures include additional cell types in addition to adipocytes, such as pre-adipocytes or endothelial cells (Sonda et al., (2008) Endocrinology 149: 4794-4798), or generally using adipocytes. differentiated in vitro from stem cells (Choi et al, (2010) Tissue Engineering: Part C, Kang et al (2007) Biomaterials 28: 450-458) or pre-adipocytes (Daya et al (2007) Differentiation 75: 360-370, WO 2007/113591, Stacey et al (2009) Tissue Engineering: Part A 15: 3389-3399), whose phenotype is relatively remote from that of mature adipocytes isolated from adipose tissue (see FIGS. 1 to 3).
Ainsi, ces systèmes n'apparaissent pas être spécifiquement et directement représentatifs du métabolisme d'adipocytes matures isolés du tissu adipeux. Thus, these systems do not appear to be specifically and directly representative of the metabolism of mature adipocytes isolated from adipose tissue.
C'est donc un objet de la présente invention que de fournir un tel système de culture, proche de la physiologie, notamment humaine. It is therefore an object of the present invention to provide such a culture system, close to physiology, especially human.
Résumé de l'invention Summary of the invention
La présente invention résulte de la mise en évidence inattendue, par les inventeurs, que des adipocytes matures isolés de tissu adipeux pouvaient être cultivés, en l'absence d'autres types cellulaires, à l'aide d'un support de culture tridimensionnel et que les adipocytes ainsi cultivés conservent pendant au moins 48 h un phénotype semblable à celui d'adipocytes matures fraîchement isolés. The present invention results from the unexpected finding by the inventors that mature adipocytes isolated from adipose tissue could be cultured, in the absence of other cell types, using a three-dimensional culture support and that the adipocytes thus cultured retain for at least 48 hours a phenotype similar to that of freshly isolated mature adipocytes.
La présente invention concerne ainsi un procédé de culture d'adipocytes, dans lequel une population homogène d'adipocytes matures isolés de tissu adipeux est cultivée sur un support de culture tridimensionnel. La présente invention concerne également une culture d'adipocyte, comprenant une monoculture d'adipocytes matures isolés de tissu adipeux au contact d'un support de culture tridimensionnel. The present invention thus relates to a method of culturing adipocytes, wherein a homogeneous population of mature adipocytes isolated from adipose tissue is cultured on a three-dimensional culture support. The present invention also relates to an adipocyte culture, comprising a monoculture of mature adipocytes isolated from adipose tissue in contact with a three-dimensional culture support.
L'invention concerne également l'utilisation d'une culture d'adipocytes selon l'invention, pour le criblage de composés modulant le métabolisme adipocytaire. The invention also relates to the use of an adipocyte culture according to the invention, for the screening of compounds modulating adipocyte metabolism.
L'invention concerne également une méthode de criblage de composés modulant le métabolisme adipocytaire, dans laquelle : The invention also relates to a method for screening compounds that modulate adipocyte metabolism, in which:
on met en contact un composé à cribler avec une culture d'adipocytes selon l'invention ; a compound to be screened is contacted with a culture of adipocytes according to the invention;
- on détermine si au moins un paramètre représentatif du métabolisme adipocytaire de la culture d'adipocytes est modifié par rapport à une culture d'adipocytes selon l'invention n'ayant pas été mise en contact avec le composé à cribler ; it is determined whether at least one representative parameter of the adipocyte metabolism of the adipocyte culture is modified with respect to a culture of adipocytes according to the invention which has not been brought into contact with the compound to be screened;
on sélectionne le composé s'il modifie au moins paramètre représentatif du métabolisme adipocytaire. the compound is selected if it modifies at least one representative parameter of the adipocyte metabolism.
Description détaillée de l'invention Detailed description of the invention
Comme on l'entend ici l'expression « adipocytes matures » représente des adipocytes différenciés. Les adipocytes matures peuvent être aisément identifiés par l'homme du métier. En particulier, un adipocyte mature selon l'invention présente habituellement une vacuole lipidique unique, une activité lipolytique, notamment inductible par des agents β-adrénergiques, tels que l'adrénaline et la noradrénaline, ainsi qu'une sensibilité à l'insuline, en particulier définie par un transport inductible par l'insuline, depuis le milieu extracellulaire vers le milieu intracellulaires, de glucose et d'acides gras, lequel transport est notamment lié à la translocation insulino-dépendante, au sein de la membrane plasmique des adipocytes matures, des transporteurs GLUT-4 et CD36 respectivement. Les adipocytes matures selon Γ invention se distinguent en particulier des pré-adipocytes, notamment en ce que l'expression du marqueur spécifique des pré-adipocytes DelKl/Prefl, bien connu de l'homme du métier, qui peut être mesurée par PCR en temps réelle, est essentiellement absente dans les adipocytes matures selon l'invention. Les adipocytes matures selon l'invention sont isolés de tissu adipeux. Ainsi, les adipocytes matures selon l'invention sont notamment tels qu'ils ne proviennent pas de la différenciation in vitro de précurseurs adipocytaires, tels que les pré- adipocytes ou les cellules souches, totipotentes, multipotentes, ou pluripotentes. As used herein, the term "mature adipocytes" represents differentiated adipocytes. The mature adipocytes can be easily identified by those skilled in the art. In particular, a mature adipocyte according to the invention usually has a single lipid vacuole, a lipolytic activity, in particular inducible by β-adrenergic agents, such as adrenaline and norepinephrine, as well as an insulin sensitivity, in particular particular defined by insulin-inducible transport, from the extracellular medium to the intracellular medium, glucose and fatty acids, which transport is particularly related to the insulin-dependent translocation, within the plasma membrane of mature adipocytes, GLUT-4 and CD36 carriers respectively. The mature adipocytes according to the invention are distinguished in particular from pre-adipocytes, in particular in that the expression of the specific marker of the pre-adipocytes DelK1 / Prefl, well known to those skilled in the art, which can be measured by PCR in time. real, is essentially absent in mature adipocytes according to the invention. The mature adipocytes according to the invention are isolated from adipose tissue. Thus, mature adipocytes according to the invention are especially such that they do not come from the in vitro differentiation of adipocyte precursors, such as pre-adipocytes or stem cells, totipotent, multipotent, or pluripotent.
S'agissant du tissu adipeux selon l'invention, il peut provenir de n'importe quelle espèce animale. Toutefois, on préfère que le tissu adipeux selon l'invention ait été prélevé chez un ou plusieurs individus humains. As regards the adipose tissue according to the invention, it can come from any animal species. However, it is preferred that the adipose tissue according to the invention has been removed from one or more human individuals.
Les adipocytes matures peuvent être isolés à partir de tissu adipeux par de nombreuses méthodes bien connues de l'homme du métier, prenant notamment avantage de la faible densité des adipocytes matures. En particulier, le tissu adipeux peut être traité à la collagénase, puis après digestion, être filtré sur de la gaze de coton tissé ; le filtrat est laissé à décanter dans un milieu aqueux et une population homogène d' adipocytes matures selon l'invention peut être récupérée en récoltant les cellules flottantes. The mature adipocytes can be isolated from adipose tissue by many methods well known to those skilled in the art, taking particular advantage of the low density of mature adipocytes. In particular, the adipose tissue can be treated with collagenase, then after digestion, be filtered on woven cotton gauze; the filtrate is left to decant in an aqueous medium and a homogeneous population of mature adipocytes according to the invention can be recovered by harvesting the floating cells.
Comme on l'entend ici, « une population homogène d' adipocytes matures » est notamment telle qu'elle est essentiellement exempte d'autres types cellulaires, notamment de cellules endothéliales ou de pré-adipocytes. En particulier, une population homogène d' adipocytes matures selon l'invention comprend moins de 10%, plus particulièrement moins de 5% de cellules autres que des adipocytes matures, notamment de pré-adipocytes. La quantité de pré-adipocytes dans une population homogène d' adipocytes matures peut être déterminée en quantifiant le nombre de cellules exprimant un marqueur spécifique des pré-adipocytes, tel que DelKl/Prefl par exemple. As used herein, "a homogeneous population of mature adipocytes" is especially such that it is substantially free of other cell types, including endothelial cells, or preadipocytes. In particular, a homogeneous population of mature adipocytes according to the invention comprises less than 10%, more particularly less than 5% of cells other than mature adipocytes, in particular pre-adipocytes. The amount of pre-adipocytes in a homogenous population of mature adipocytes can be determined by quantifying the number of cells expressing a specific preadipocyte marker, such as DelK1 / Prefl for example.
Comme on l'entend ici, une « monoculture d' adipocytes mature » est une culture d'une population homogène d'adipocytes matures. As used herein, a "mature adipocyte monoculture" is a culture of a homogeneous population of mature adipocytes.
Une population homogène d'adipocytes matures est dite « cultivée » ou en « culture » lorsqu'elle est incubée, c'est-à-dire conservée in vitro, dans des conditions permettant la survie des cellules constituant la population. De telles conditions ainsi que les milieux de culture adéquats sont bien connus de l'homme du métier. Ces milieux de culture sont tels qu'ils contiennent l'ensemble des éléments, notamment nutritifs, susceptibles d'assurer la survie des cellules constituant la population pendant au moins 12 h, de préférence au moins 24 h, plus préférablement au moins 48 h. A titre d'exemple, la population peut être incubée dans un milieu DMEM/F12, 1% Pénicilline-Streptomycine, 50 nM Insuline, sous agitation, à 37°C et dans une atmosphère à 5% C02, le milieu étant régulièrement renouvelé. De manière avantageuse, les milieux de culture des adipocytes matures selon l'invention peuvent comprendre des composés destiné à moduler l'activité métabolique des adipocytes matures, tels que la forskoîine et la dexaméthasone, par exemple. Par ailleurs, la culture de la population d'adipocytes matures est de préférence réalisée pendant au moins 3 h, 6 h, 12 h, 24 h, ou 48 h. A homogeneous population of mature adipocytes is said to be "cultured" or "cultured" when it is incubated, that is to say preserved in vitro, under conditions allowing the survival of the cells constituting the population. Such conditions as well as suitable culture media are well known to those skilled in the art. These culture media are such that they contain all the elements, in particular nutrients, capable of ensuring the survival of the cells constituting the population for at least 12 hours, preferably at least 24 hours, more preferably at least 48 h. For example, the population can be incubated in a DMEM / F12 medium, 1% Penicillin-Streptomycin, 50 nM Insulin, with stirring, at 37 ° C. and in an atmosphere at 5% C0 2 , the medium being regularly renewed. . Advantageously, the mature adipocyte culture media according to the invention may comprise compounds intended to modulate the metabolic activity of mature adipocytes, such as forskinin and dexamethasone, for example. Moreover, the culture of the mature adipocyte population is preferably carried out for at least 3 h, 6 h, 12 h, 24 h, or 48 h.
Selon l'invention, les adipocytes matures sont « cultivés sur un support de culture tridimensionnel » lorsque les adipocytes sont au contact du support, c'est dire qu'ils reposent sur le support ou qu'ils adhèrent au support. According to the invention, the mature adipocytes are "cultured on a three-dimensional culture support" when the adipocytes are in contact with the support, ie they rest on the support or they adhere to the support.
Dans un mode de réalisation particulier, le procédé de culture d'adipocytes scion l'invention comprend les étapes suivantes : In a particular embodiment, the method for culturing adipocytes according to the invention comprises the following steps:
mettre en contact une population homogène d'adipocytes avec un support de culture tridimensionnel ; contacting a homogeneous population of adipocytes with a three-dimensional culture support;
incuber les adipocytes matures en contact avec le support de culture, en particulier dans des conditions permettant la survie des cellules, notamment pendant au moins 48 h. incubate the mature adipocytes in contact with the culture medium, in particular under conditions allowing the survival of the cells, in particular for at least 48 hours.
Un « support de culture tridimensionnel » selon l'invention est constitué d'un matériau, notamment biocompatible, adapté à l'obtention d'une culture tridimensionnelle de cellules ; autrement dit, le support de culture tridimensionnel est adapté, en particulier, à l'obtention de plusieurs couches de cellules superposées. Ainsi, un support de culture ne permettant que la culture d'un tapis cellulaire bidimensionnel, à savoir une monocouche de cellules, n'est pas un support de culture tridimensionnel selon l'invention. A "three-dimensional culture support" according to the invention consists of a material, in particular biocompatible, adapted to obtain a three-dimensional cell culture; in other words, the three-dimensional culture support is adapted, in particular, to obtaining several layers of superposed cells. Thus, a culture support allowing only the culture of a two-dimensional cellular mat, namely a monolayer of cells, is not a three-dimensional culture support according to the invention.
De préférence, le support de culture tridimensionnel selon l'invention est un hydrogel. Plus préférablement, le support de culture tridimensionnel selon l'invention est un hydrogel formé de l'association non covalente de peptides comprenant de 10 à 30 résidus, tels que des peptides comprenant une répétition de la séquence R-A-D-A, et notamment une séquence R-A-D-A-R-A-D-A-R-A-D-A-R-A- D-A (SEQ ID NO : 11). Les peptides formant l'hydrogel peuvent être modifiés, par exemple par l'adjonction de groupements acétyles sur l'extrémité N-terminale des peptides et par l'adjonction d'un groupement -N¾ à l'extrémité C-terminale des peptides. Ainsi, les peptides peuvent être représentés par la séquence : Ac-R-A-D-A- R-A-D-A-R-A-D-A-R-A-D-A-CONH2. De manière particulièrement préférée, le support de culture tridimensionnel selon l'invention est l'hydrogel PuraMatrix™ (3DM, Inc.). Preferably, the three-dimensional culture support according to the invention is a hydrogel. More preferably, the three-dimensional culture support according to the invention is a hydrogel formed from the non-covalent association of peptides comprising from 10 to 30 residues, such as peptides comprising a repetition of the RADA sequence, and in particular a RADARADARADARA-DA sequence. (SEQ ID NO: 11). The peptides forming the hydrogel can be modified, for example by the addition of acetyl groups on the N-terminus of the peptides and by the addition of a group -N¾ at the C-terminus of the peptides. Thus, the peptides can be represented by the sequence: Ac-RADA-RADARADARADA-CONH 2 . More preferably, the three-dimensional culture carrier according to the invention is the hydrogel PuraMatrix ™ (3DM, Inc.).
Les composés susceptibles d'être criblés selon l'invention peuvent être de tout type. En particulier, il peut s'agir de composés issus de chimiothèques. Par ailleurs, la culture d'adipocytes selon l'invention peut être utilisée pour cribler des composés activant la lipolyse, ou des composés activant le facteur de transcription PPARy2 ; ou des composés modulant la sensibilité à l'insuline. The compounds which can be screened according to the invention can be of any type. In particular, they may be compounds from chemical libraries. Moreover, the culture of adipocytes according to the invention can be used to screen compounds activating lipolysis, or compounds activating PPARy2 transcription factor; or compounds that modulate insulin sensitivity.
Comme on l'entend ici, la lipolyse (ou activité lipolytique), la sensibilité à l'insuline, ou l'activité du facteur de transcription PPARy2, sont des paramètres représentatifs du métabolisme adipocytaire. As used herein, lipolysis (or lipolytic activity), insulin sensitivity, or activity of the PPARγ2 transcription factor, are representative parameters of adipocyte metabolism.
La détermination de la lipolyse peut être mise en œuvre par de nombreuses méthodes bien connues de l'homme du métier. En particulier, Γ activité lipolytique peut être déterminée en mesurant la quantité de glycérol et d'acides gras libres libérée par une culture d'adipocytes selon l'invention, notamment par spectrophotométrie comme cela est décrit dans Lacasa et al. (1991) Endocrinology 128:747-753. La sensibilité à l'insuline des adipocytes peut être évaluée d'après la mesure du transport du glucose dans l'adipocyte comme cela est décrit dans Wood et al. (2007) B toc hem. Biophys. Res. Commun. 361:468-473. L'activité du facteur de transcription PPARy2 peut être mesurée en déterminant la quantité d'ARNm le codant dans une cellule, par exemple par RT-PCR ou par mesure directe de l'activité de liaison à ses sites spécifiques de l'ADN comme cela est notamment décrit dans Keophiphath et al. (2009) J. Nutr. 139 : 2055-2060. The determination of lipolysis can be carried out by many methods well known to those skilled in the art. In particular, lipolytic activity can be determined by measuring the amount of glycerol and free fatty acids released by an adipocyte culture according to the invention, in particular by spectrophotometry as described in Lacasa et al. (1991) Endocrinology 128: 747-753. The insulin sensitivity of adipocytes can be evaluated from the measurement of glucose transport in the adipocyte as described in Wood et al. (2007) B toc hem. Biophys. Res. Common. 361: 468-473. The activity of the transcription factor PPARy2 can be measured by determining the amount of mRNA encoding it in a cell, for example by RT-PCR or by direct measurement of the binding activity at its specific DNA sites, such as is described in particular in Keophiphath et al. (2009) J. Nutr. 139: 2055-2060.
Description des figures Description of figures
Figures 1 , 2 et 3 Figures 1, 2 and 3
Les figures 1 à 3 représentent respectivement le niveau d'expression relative (axe des ordonnées, unités arbitraires) mesuré par PCR en temps réel de trois marqueurs spécifiques des adipocytes matures, à savoir PPARy2, FABP4 (un transporteur d'acide gras dont le gène est une cible de PPARy2), et une adipokine, l'adiponectine, dans des adipocytes matures fraichement isolés de tissu adipeux d'une part (barres noires) et dans des adipocytes obtenus par différenciation in vitro de pré-adipocytes comme cela est décrit dans Lacasa et al Endocrinology 148:868-877, d'autre part (barres blanches). Figures 1 to 3 respectively represent the level of relative expression (ordinate axis, arbitrary units) measured by real-time PCR of three specific markers of mature adipocytes, namely PPARy2, FABP4 (a fatty acid transporter whose gene is a target of PPARy2), and an adipokine, adiponectin, in mature adipocytes freshly isolated from adipose tissue on the one hand (black bars) and in adipocytes obtained by in vitro differentiation of pre-adipocytes as described in Lacasa et al. Endocrinology 148: 868-877, on the other hand ( white bars).
Figure 4 Figure 4
La figure 4 représente un gel d'immunoélectrophorèse de lysats cellulaires préparés à partir d'adipocytes matures maintenus en culture sur le support tridimensionnel pendant 48 heures (3D) et d'adipocytes matures fraichement isolés (J0) puis marqués à l'aide d'un anticorps dirigé contre le marqueur adipocytaire aP2/FABP4 et d'un anticorps dirigé contre un témoin positif (actine). 4 shows a cell lysates immunoelectrophoresis gel prepared from mature adipocytes maintained in culture on the three-dimensional support for 48 hours (3D) and freshly isolated mature adipocytes (J0) then labeled using an antibody directed against the adipocyte marker aP2 / FABP4 and an antibody directed against a positive control (actin).
Figures 5 et 6 Figures 5 and 6
Les figures 5 et 6 représentent respectivement les niveaux d'activité lipolytique (axe des ordonnées, en unités arbitraires) basale et stimulée par la forskoline (FK) d'adipocytes matures cultives (i) dans le support de culture tridimensionnel (3D) en l'absence (barres blanches) et en présence de dexaméthasone (Dex) (barres noires), et (ii) en monocouches (2D) (barres grisées), en fonction de la durée de culture (axe des abscisses, en jours). L'expérience présentée est représentative d'un ensemble de trois expériences répliquées. Figures 5 and 6 show levels of lipolytic activity (y-axis in arbitrary units) basal and stimulated by forskolin (FK) of mature adipocytes grown (i) in the three-dimensional culture substrate (3D) in the absence (white bars) and in the presence of dexamethasone (Dex) (black bars), and (ii) in monolayers (2D) (shaded bars), depending on the culture time (x axis, in days). The experiment presented is representative of a set of three replicated experiments.
Figures 7 et 8 Figures 7 and 8
Les figures 7 et 8 représentent respectivement les quantités de leptine et d'adiponectine sécrétées (axe des ordonnées, en pg/ml/24h) par des adipocytes mature cultivés dans le support de culture tridimensionnel (3D) en l'absence (barres blanches) et en présence de dexaméthasone (Dex) (barres noires). L'expérience présentée est représentative d'un ensemble de trois expériences répliquées. Figures 7 and 8 respectively represent the secreted amounts of leptin and adiponectin (y-axis, in μg / ml / 24h) by mature adipocytes cultured in the three-dimensional culture support (3D) in the absence (white bars) and in the presence of dexamethasone (Dex) (black bars). The experiment presented is representative of a set of three replicated experiments.
Figure 9 Figure 9
La figure 9 représente l'expression génique relative de marqueurs adipocytaires (axes des ordonnées, unités arbitraires) mesurée par PCR en temps réel à partir d'extraits d'adipocytes matures fraichement isolés (barres noires) et d'adipocytes mature maintenus 48 h en culture dans le support de culture tridimensionnel (barres blanches). FIG. 9 represents the relative gene expression of adipocyte markers (ordinate axes, arbitrary units) measured by real-time PCR from extracts of freshly isolated mature adipocytes (black bars) and mature adipocytes. maintained for 48 hours in culture in the three-dimensional culture support (white bars).
Figure 10 Figure 10
La figure 10 représente un gel d'immunoélectrophorèse de lysats cellulaires préparés à partir d'adipocytes matures maintenus en culture sur le support tridimensionnel pendant 48 heures (3D) et d'adipocytes matures fraîchement isolés (2D) incubés en présence d'insuline ( 1 nM) aux temps indiqués puis marqués à l'aide d'un anticorps dirigé contre la forme phosphorylée d'Akt et d'un anticorps dirigé contre un témoin positif (actine). Figure 10 shows a cell lysates immunoelectrophoresis gel prepared from mature adipocytes maintained in culture on the three-dimensional support for 48 hours (3D) and freshly isolated mature adipocytes (2D) incubated in the presence of insulin (1 nM) at the indicated times then labeled with an antibody directed against the phosphorylated form of Akt and an antibody directed against a positive control (actin).
Exemples Examples
A. Matériels et Méthodes A. Materials and Methods
1. Matériels 1. Materials
L'hydrogel peptidique BDTM PuramatrixTM est obtenu de BD Biosciences (Two oak Park, Bedford, MA, USA). The BDTM Puramatrix ™ peptide hydrogel is obtained from BD Biosciences (Two Oak Park, Bedford, MA, USA).
Les anticorps primaires anti cavéoline- 1 (N-20, SC-894) et antiCD36 (1.BB.3414, CS-70642) utilisés proviennent de Santa Cruz Biotcchnology (Santa Cruz, CA, USA). Les anticorps correspondants couplés à Cy3 sont obtenus auprès de GE healthcare (Little Chalfont, UK). The primary anti-caveolin-1 (N-20, SC-894) and antiCD36 (1.BB.3414, CS-70642) antibodies used are from Santa Cruz Biotcchnology (Santa Cruz, CA, USA). The corresponding Cy3-coupled antibodies are obtained from GE Healthcare (Little Chalfont, UK).
2. Préparation des adipocytes matures isolés 2. Preparation of isolated mature adipocytes
Les adipocytes matures sont isolés par traitement à la collagénase de tissu adipeux humain. Le tissu adipeux humain sous-cutané de femmes jeunes (<45 ans) et non obèses (IMC<30) est découpé dans du milieu de digestion (DMEM, 2% albumine pauvre en acides gras (A6003, Sigma St Louis, MI, USA), lmg/ml collagénase A (Roche Diagnostics, Mannhein, Allemagne) dans la proportion de lg de tissu pour 2 ml de milieu de digestion dans des tubes en polypropylène. Les tubes sont placés à 37°C pendant 30 minutes sous agitation (200 cycles /minute). Après digestion, le milieu est filtré sur de la gaze de coton tissé. Les adipocytes matures sont laissés à décanter par flottaison pendant 5 minutes puis sont lavés 3 fois avec 5 volumes de saccharose 10%. A la fin du dernier lavage, le saccharose est soutiré et les adipocytes matures sont prêts à être incorporés dans l'hydrogel Puramatrix™. The mature adipocytes are isolated by collagenase treatment of human adipose tissue. The subcutaneous human adipose tissue of young (<45 years old) and non-obese (BMI <30) women is cut out of digestion media (DMEM, 2% low fatty acid albumin (A6003, Sigma St Louis, MI, USA). ), 1 mg / ml collagenase A (Roche Diagnostics, Mannheim, Germany) in the proportion of 1 g of tissue per 2 ml of digestion medium in polypropylene tubes The tubes are placed at 37 ° C. for 30 minutes with shaking (200 cycles / minute) After digestion, the medium is filtered on woven cotton gauze The mature adipocytes are allowed to settle by flotation for 5 minutes and then washed 3 times with 5 volumes of sucrose 10% At the end of the last washing, the sucrose is withdrawn and the mature adipocytes are ready to be incorporated into the Puramatrix ™ hydrogel.
3. Préparation de l'hydrogel contenant les adipocytes matures 3. Preparation of the hydrogel containing the mature adipocytes
Comme préconisé par le fabricant, l'hydrogel est soniqué pendant 30 minutes afin de réduire sa viscosité. Le gel est ensuite dilué V/V avec du saccharose 20% puis centrifugé 5 minutes à 1000g pour éliminer les bulles d'air. Les adipocytes matures lavés sont rapidement incorporés à ce mélange avec une homogénéisation par aspiration douce à la pipette. Le mélange adipocytes/gel est ensuite distribué dans la proportion de 100 μL· par puits dans des plaques de culture de 96 puits. Très rapidement, le milieu d'incubation ( 150 μί) (DMEM/F12, 1% Pénicilline- Streptomycine, 50 nM Insuline) (DMI) est ajouté dans les puits et les plaques placées dans un incubateur à 37°C sous atmosphère à 5% de C02. Après 30 minutes, le milieu DMI est renouvelé. Le changement de milieu est répété deux fois. Le lendemain, le milieu DMI est changé et cette opération est renouvelée tous les jours. Dans certaines expériences, le DMI contient 100 nM dexaméthasone (Sigma Aldricht, saint Louis, MO, USA) ou 100 nM de rosiglitazone (Merck, Nottingham, UK). As recommended by the manufacturer, the hydrogel is sonicated for 30 minutes to reduce its viscosity. The gel is then diluted V / V with 20% sucrose and then centrifuged for 5 minutes at 1000 g to remove the air bubbles. The washed mature adipocytes are rapidly incorporated into this mixture with homogenization by gentle suction with the pipette. The adipocytes / gel mixture is then distributed in the proportion of 100 μl · per well in 96-well culture plates. Very rapidly, the incubation medium (150 μl) (DMEM / F12, 1% Penicillin-Streptomycin, 50 nM Insulin) (DMI) is added to the wells and the plates placed in an incubator at 37 ° C. under a 5% atmosphere. of C0 2 . After 30 minutes, the DMI medium is renewed. The change of medium is repeated twice. The next day, the medium DMI is changed and this operation is renewed every day. In some experiments, DMI contains 100 nM dexamethasone (Sigma Aldricht, St. Louis, MO, USA) or 100 nM rosiglitazone (Merck, Nottingham, UK).
4. Mesure de l'activité lipolvtique 4. Measurement of lipolvetic activity
Les puits contenant l'ensemble hydro gel/adipocytes sont lavés une première fois avec 150 μΐ^ de milieu Krebs Ringer (115 m M NaCl, 4,7 m M KC1, 1,2 m M CaCl2, 1 ,2 m M KH2P04, 1 ,2 mM MgS04, 20 m NaHC03), 5 m M glucose, 3% Albumine pauvre en acides gras (KRB/ALB) pour équilibrer l'hydrogel. 100 μϊ, de RB/ALB contenant soit 0,1% DMSO ou 10 μΜ Forskoline (Sigma) sont distribués dans les puits. Les plaques sont ensuite placées dans Γ incubateur pendant 4 heures. Le milieu est prélevé et placé 10 minutes à 70°C afin d'inactiver les enzymes adipocytaires pouvant interférer avec le dosage du glycérol. Le glycérol libéré est dosé par spectrophotométrie (Trousse de dosage du Glycerol, R-Biopharm) comme décrit dans Lacasa et al. (1991) Endocrinology 128:747-753. Wells containing all hydro gel / adipocytes are washed once with 150 medium μΐ ^ Krebs Ringer (115 mM NaCl, 4.7 mM KC1, 1.2 mM CaCl 2, 1, 2 m M KH 2 P0 4 , 1, 2 mM MgSO 4 , 20 m NaHCO 3 ), 5 m M glucose, 3% albumin low in fatty acids (KRB / ALB) to balance the hydrogel. 100 μl of RB / ALB containing either 0.1% DMSO or 10 μΜ Forskolin (Sigma) are distributed in the wells. The plates are then placed in the incubator for 4 hours. The medium is removed and placed for 10 minutes at 70 ° C in order to inactivate the adipocyte enzymes that can interfere with the glycerol assay. The glycerol released is assayed spectrophotometrically (Glycerol Assay Kit, R-Biopharm) as described in Lacasa et al. (1991) Endocrinology 128: 747-753.
5. Mesure de la sécrétion des adipokines 5. Measurement of adipokine secretion
Le milieu DMI est prélevé 24 heures après le dernier changement de milieu. The DMI medium is taken 24 hours after the last change of medium.
Le dosage des adipokines (leptine, adiponectine) est réalisé directement sur ce milieu (100 μΐ) par la technique ELIS A (Duoset, R&D Systems, Minneapolis, MN USA) comme décrit par le fabricant. The dosage of adipokines (leptin, adiponectin) is carried out directly on this medium (100 μl) by the ELISA technique (Duoset, R & D Systems, Minneapolis, MN USA) as described by the manufacturer.
6. Mesure de l'expression génique 6. Measurement of gene expression
Le milieu DMI est rapidement éliminé des puits et l'ensemble gel/adipocytes est homogénéisé par le tampon de lyse dans la proportion de 1ml de tampon de lyse/ lml d'ensemble gel/adipocytes. Les ARN sont ensuite extraits avec au préalable un traitement délipidant par le chloroforme en utilisant le kit d'extraction RNeasy (Qiagen, Courtaboeuf, France) comme décrit dans Lacasa et al. (2007) Endocrinology 148:868-877. Les ARNs totaux (1 μ«) sont ensuite transcrits en ADNc comme décrits dans Lacasa et al. (2007) Endocrinology 148:868-877. La liste des amorces utilisées est indiquée dans le tableau 1. Les essais de PCR en temps réel sont effectués avec 25ng d'ADNc et les amorces sens et antisens en utilisant le mélange PCR universel Sybergreen (Applied Biosystems, Minneapoîis, MN USA) et mesurés dans un appareil de détection (Applied Biosystems). Toutes les valeurs sont normalisées par rapport à l'expression de la protéine ribosomalc RPLPO. The DMI medium is rapidly removed from the wells and the gel / adipocyte assembly is homogenized by the lysis buffer in the proportion of 1 ml of lysis buffer / lml of gel / adipocyte assembly. The RNAs are then extracted with chloroform delipidation treatment beforehand using the RNeasy extraction kit. (Qiagen, Courtaboeuf, France) as described in Lacasa et al. (2007) Endocrinology 148: 868-877. The total (1 μ ") RNAs are then transcribed into cDNA as described in Lacasa et al. (2007) Endocrinology 148: 868-877. The list of primers used is shown in Table 1. The PCR test in real time are performed with 25ng cDNA and forward and reverse primers using the universal PCR mixture Sybergreen (Applied Biosystems, Minneapoîis, MN USA) and measured in a detection device (Applied Biosystems). All values are normalized to RPLPO ribosomal protein expression.
Tableau 1 : Amorces utilisées Table 1: Primers used
7. Techniques d'immunotluorcsccnce 7. Techniques immunotluorcsccnce
Après élimination du milieu DMI et lavage par du PBS, l'ensemble gel/adipocytes est déposé dans des puits de plaques à 96 puits et fixé par 4% paraformaldéhyde (PAF) pendant 1 heure. Après inactivation du PAF par traitement par un tampon PBS/Glycinc 0,1 M, les cellules sont perméabilisées 5 minutes à température ambiante par 0,1% Triton X-100 dans du PBS/3% albumine. Les sites non spécifiques sont bloqués par le tampon PBS/3% albumine pendant 4 heures à température ambiante puis les anticorps primaires sont ajoutés et l'incubation se poursuit pendant 14 heures à 4°C. Après 6 lavages (1 heure), l'ensemble gel/adipocytes est incubé avec les anticorps secondaires pendant 4 heures à température ambiante dans l'obscurité. L'ensemble gel/adipocytes est ensuite lavé (1 heure) et des fragments de ce gel sont déposés dans du milieu de montage (Fluomount, Birmingham, Alabama, USA) entre lame et lamelles. Les lames sont examinées en fluorescence après 24 heures. After removal of the DMI medium and washing with PBS, the gel / adipocyte assembly is deposited in wells of 96-well plates and fixed with 4% paraformaldehyde (PAF) for 1 hour. After inactivation of the PAF by treatment with PBS / 0.1 M glycine buffer, the cells are permeabilized for 5 minutes at room temperature with 0.1% Triton X-100 in PBS / 3% albumin. Non-specific sites are blocked by PBS / 3% albumin buffer for 4 hours at room temperature, then primary antibodies are added and incubation is continued for 14 hours at 4 ° C. After 6 washes (1 hour), the gel / adipocyte assembly is incubated with the secondary antibodies for 4 hours at room temperature in the dark. The gel / adipocyte assembly is then washed (1 hour) and fragments of this gel are deposited in mounting medium (Fluomount, Birmingham, Alabama, USA) between blade and lamellae. The slides are examined in fluorescence after 24 hours.
8. Techniques d'immuno-clectrophorèsc 8. Techniques immune clectrophorèsc
Après élimination du milieu DMI et lavage par du PBS, l'ensemble gel/adipocytes est rapidement lysé par un volume de tampon de lyse (PBS, 2% IGEPAL, 0,2% SDS, 1% desoxycholate de sodium) contenant un mélange d'inhibiteurs de protéases et de phosphatases (Complète mini et Phosphostop, Roche diagnostics). L'homogénat est ensuite gardé 15 minutes à 4°C puis centrifugé 10 minutes à 5000g. Le lysat cellulaire est ensuite collecté et dilué dans du tampon de Laemmli et soumis à une électrophorèse comme décrit dans Lacasa et al. (2007) Endocrinology 148:868-877. Après transfert des protéines sur membrane de cellulose, une coloration au rouge Ponceau permet de vérifier la charge et la qualité du transfert. Les membranes sont ensuite incubées avec les anticorps primaires à 4°C pendant 14 heures. Puis, après lavages, les membranes sont incubées avec les anticorps secondaires (GE Healthcare, Littlc Chai font, U ). Les signaux sont détectés par chimioluminescence (Détection ECL, GE Healthcare) et quantifiés par densitométrie. After removal of the DMI medium and washing with PBS, the gel / adipocyte assembly is rapidly lysed with a volume of lysis buffer (PBS, 2% IGEPAL, 0.2% SDS, 1% sodium desoxycholate) containing a mixture of protease inhibitors and phosphatases (Complete mini and Phosphostop, Roche diagnoses). The homogenate is then kept 15 minutes at 4 ° C. and then centrifuged for 10 minutes at 5000 g. The cell lysate is then collected and diluted in Laemmli buffer and electrophoresed as described in Lacasa et al. (2007) Endocrinology 148: 868-877. After transfer of the proteins on cellulose membrane, Ponceau red staining allows to check the load and the quality of the transfer. The membranes are then incubated with the primary antibodies at 4 ° C for 14 hours. Then, after washing, the membranes are incubated with the secondary antibodies (GE Healthcare, Littlc Chai font, U). The signals are detected by chemiluminescence (ECL Detection, GE Healthcare) and quantified by densitometry.
9. Mesure de la sensibilité à l'insuline 9. Measurement of insulin sensitivity
Les puits contenant Phydro gel/adipocytes déprivés la veille en insuline sont incubés avec le milieu d'incubation ( 150 (DMEM/F 12 et 10 nM Insuline). Les plaques sont ensuite placées dans l'incubateur pendant 15 à 30 minutes. Le gel/adipocytes est rapidement lysé par un volume de tampon de lyse (PBS, 2% IGEPAL, 0,2% SDS, 1% déoxycholate de sodium) contenant un mélange d'inhibiteurs de protéases et de phosphatases (Complète mini et Phosphostop, Roche diagnostics) L'homogénat est ensuite gardé 15 minutes à 4°C puis centrifugé 10 minutes à 5000 g. Le lysat est ensuite collecté et dilué dans du tampon de Laemmli et soumis à une électrophorèse comme décrit précédemment. Les membranes sont alors incubées avec les anticorps primaires respectivement dirigés contre la forme phosphorylée de Akt au niveau de la Ser473 (réf. G7441 Promega) ou contre l'actine (témoin positif) (MAB1501R, Millipore) à 4°C pendant 14 heures. Puis après lavages, les membranes sont incubées avec les anticorps secondaires (GE Healthcare, Little Chalfont, UK). Les signaux sont détectés par chimioluminescence {Détection ECL, GE Healthcare) et quantifiés par densitométrie. Wells containing Phydro gel / déprivés adipocytes insulin standby times are incubated with incubation medium (150 (DMEM / F 12 and 10 nM Insulin). The plates are then placed in the incubator for 15 to 30 minutes. The gel / adipocytes is rapidly lysed with a volume of lysis buffer (PBS, 2% IGEPAL, 0.2% SDS, 1% sodium deoxycholate) containing a mixture of protease inhibitors and phosphatases (Complete mini and Phosphostop, Roche diagnostics) The homogenate is then kept 15 minutes at 4 ° C and then centrifuged for 10 minutes at 5000 g. The lysate is then collected and diluted in Laemmli buffer and electrophoresed as previously described. The membranes are then incubated with the primary antibodies respectively against the phosphorylated form of Akt at Ser 473 (ref G7441 Promega) or against actin (positive control) (MAB1501R, Millipore) at 4 ° C for 14 hours. . After washing, the membranes are incubated with the secondary antibodies (GE Healthcare, Little Chalfont, UK). The signals are detected by chemiluminescence (ECL detection, GE Healthcare) and quantified by densitometry.
B. Résultats B. Results
1. Homogénéité de la population adipocytaire mature 1. Homogeneity of the mature adipocyte population
La proportion de pré-adipocytes contaminants présent dans la population d'adipocytes matures isolés de tissu adipeux utilisée pour la culture a été déterminée en mesurant l'expression par PCR en temps réel du marqueur Del l/Prefl spécifique des pré-adipocytes. The proportion of contaminating pre-adipocytes present in the mature adipocyte population isolated from adipose tissue used for culture was determined by measuring the real-time PCR expression of the pre-adipocyte specific Del 1 / Prefl marker.
Cette mesure montre que la population d'adipocytes matures utilisée est essentiellement homogène, dans la mesure où elle comprend moins de 5% de pré- adipocytes (environ 4%). This measurement shows that the mature adipocyte population used is essentially homogeneous, since it comprises less than 5% of preadipocytes (approximately 4%).
2. Détection des protéines adipocytaircs 2. Detection of adipocyte proteins
Les adipocytes matures cultivés dans le support tridimensionnel formé par l'hydrogel présentent bien un aspect uniloculaire après marquage par immuno fluorescence des protéines membranaires CD36 et cavéoline-1, ce qui démontre la possibilité de détecter des protéines adipocytaircs membranaires. Par ailleurs, les lysats adipocytaircs peuvent être analysés par immuno-électrophorèse comme le montre la détection de la protéine cytosolique adipocytaire aP2/FABP4 et de l'actine (Figure 4), The mature adipocytes cultured in the three-dimensional support formed by the hydrogel do indeed exhibit a unilocular appearance after immunofluorescence labeling of the CD36 and caveolin-1 membrane proteins, which demonstrates the possibility of detecting membrane adipocyte proteins. Moreover, the adipocyte lysates can be analyzed by immunoelectrophoresis as shown by the detection of the cytosolic adipocyte protein aP2 / FABP4 and actin (FIG. 4),
3. Activité lipolytique 3. Lipolytic activity
L'activité lipolytique est mesurée en conditions basalcs et en conditions stimulées par 10 μΜ de forskoline sur les adipocytes matures maintenus dans l'hydrogel pendant 7 jours. Cette activité est également comparée à celle des mêmes cellules fraîchement isolées. Les résultats présentés dans les Figures 5 et 6 montrent que l'activité lipolytique basale ( Figure 5) et stimulée par la forskoline (Figure 6) est du même ordre que celle des adipocytes fraîchement isolés et reste constante pendant 5-7 jours. Par ailleurs, la présence de dexaméthasone (gluco corticoïde de synthèse) dans le milieu de culture ne modifie pas les activités basales et stimulées. The lipolytic activity is measured in terms basalcs conditions and stimulated with 10 μΜ forskolin in mature adipocytes maintained in the hydrogel for 7 days. This activity is also compared to that of the same freshly isolated cells. The results presented in Figures 5 and 6 show that the basal lipophilic activity (Figure 5) and forskolin-stimulated (Figure 6) is of the same order as that of freshly isolated adipocytes and remains constant for 5-7 days. Moreover, the presence of dexamethasone (synthetic glucocorticoid) in the culture medium does not modify the basal and stimulated activities.
4. Sécrétion des adipokines : adiponectine et leptine 4. Secretion of adipokines: adiponectin and leptin
La sécrétion d' adiponectine (Figure 7) et de leptine (Figure 8) est mesurée jusqu'à 7 jours de maintien des adipocytes matures dans l'hydrogel en présence ou non de dexaméthasone (glucocorticoïde de synthèse). Par ailleurs, comme le montre la Figure 7, la sécrétion de leptine diminue au cours de la culture en l'absence de dexaméthasone alors que cette sécrétion augmente en présence du glucocorticoïde démontrant ainsi que la réponse à ces hormones reste fonctionnelle dans les adipocytes en culture. La sécrétion d' adiponectine reste quant à elle constante pendant 7 jours (Figure 8). The secretion of adiponectin (FIG. 7) and leptin (FIG. 8) is measured up to 7 days of maintenance of the mature adipocytes in the hydrogel, in the presence or absence of dexamethasone (synthetic glucocorticoid). Moreover, as shown in FIG. 7, the secretion of leptin decreases during the culture in the absence of dexamethasone whereas this secretion increases in the presence of the glucocorticoid, thus demonstrating that the response to these hormones remains functional in the adipocytes in culture. . The secretion of adiponectin remains constant for 7 days (Figure 8).
5. Expression génique des adipocytes 5. Gene expression of adipocytes
L'expression de gènes adipoeytaires est comparée entre des adipocytes matures fraîchement isolés et les mêmes cellules maintenues pendant 2 jours en hydrogel. La Figure 9 montre que l'expression des adipokines (leptine et adiponectine), du facteur de transcription majeur adipocytaire PPARy2 et de ses gènes cibles aP2/FABP4 et LPL reste constante. The expression of adipoeye genes is compared between freshly isolated mature adipocytes and the same cells maintained for 2 days in hydrogel. Figure 9 shows that the expression of adipokines (leptin and adiponectin), the major adipocyte transcription factor PPARy2 and its target genes aP2 / FABP4 and LPL remains constant.
6. Mesure de la sensibilité à l'insuline 6. Measurement of insulin sensitivity
Les adipocytes constituent une cible privilégiée de l'insuline, hormone anabolique majeure. Dans les adipocytes humains, l'insuline stimule la consommation du glucose entraînant une synthèse accrue de triglycérides et en revanche inhibe la dégradation de ces lipides. L'enzyme Akt transmet les effets métaboliques de l'insuline qui provoque son activation par phosphorylation de la senne 473 (Ser473Akt). Ainsi, le niveau de phosphorylation de Akt constitue un index de sensibilité à l'insuline des cellules. Adipocytes are a prime target for insulin, a major anabolic hormone. In human adipocytes, insulin stimulates glucose consumption leading to increased synthesis of triglycerides and on the other hand inhibits the degradation of these lipids. The Akt enzyme transmits the metabolic effects of insulin which causes its activation by phosphorylation of the 473 seine (Ser 473 Akt). Thus, the phosphorylation level of Akt constitutes an index of insulin sensitivity of the cells.
L'insuline (10 nM) stimule la phosphorylation d'Akt d'une manière identique dans les adipocytes fraîchement isolés (2D) et ceux maintenus pendant 48h dans l'hydrogel (3D) indiquant ainsi un bon maintien de la réponse à l'insuline de ces cellules (Figure 10). Conclusions Insulin (10 nM) stimulates phosphorylation of Akt in an identical manner in freshly isolated (2D) adipocytes and those maintained for 48 h in the hydrogel (3D) thus indicating a good maintenance of the insulin response. of these cells (Figure 10). conclusions
Les adipocytes matures maintenus dans un support de culture tridimensionnel d'hydrogel avec un milieu d'incubation, qui peut être supplémenté avec des glucocorticoïdes et des thiazolinidinediones, présentent une activité lipolytique et de sécrétion des adipokines (leptine et adiponectine) comparable à celles d' adipocytes fraîchement isolés. De plus, les adipocytes matures maintenus dans l'hydrogel conservent pendant au moins 7 jours la capacité de réponse aux glucocorticoïdes, hormones cruciales pour le métabolisme et le développement adipocytaires (Macfarlane et al. (2008) J. Endocrinol. 197:189-204). The mature adipocytes maintained in a three-dimensional hydrogel culture medium with an incubation medium, which can be supplemented with glucocorticoids and thiazolinidinediones, exhibit lipolytic and secretion activity of adipokines (leptin and adiponectin) comparable to those of freshly isolated adipocytes. In addition, mature adipocytes maintained in the hydrogel retain for at least 7 days the ability to respond to glucocorticoids, hormones crucial for adipocyte metabolism and development (Macfarlane et al (2008) J. Endocrinol 197: 189-204). ).
Ainsi, ce système peut être utilisé pour le criblage de composés pharmacoîogiques présentant des activités lipolytiques ou d'activation du facteur de transcription adipo-spécifiques PPARy2, par exemple. Thus, this system can be used for the screening of pharmacological compounds having lipolytic activities or adipo-specific transcription factor activation PPARγ2, for example.
Par ailleurs, les inventeurs ont montré que les adipocytes matures maintenus dans un support de culture tridimensionnel d'hydrogel selon Γ invention conservent au moins 2 jours leur sensibilité à l'insuline par rapport à des adipocytes matures fraîchement isolés. Ceci confirme que la culture d'adipocyte selon Γ invention est un modèle représentatif des adipocytes matures in vivo. Furthermore, the inventors have shown that mature adipocytes maintained in three-dimensional culture carrier hydrogel according Γ invention retain at least 2 days their insulin sensitivity compared to freshly isolated mature adipocytes. This confirms that the culture of adipocyte according Γ invention is a model representative of the mature adipocytes in vivo.
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1002180A FR2960549B1 (en) | 2010-05-25 | 2010-05-25 | PROCESS FOR CULTIVATION OF ADIPOCYTES |
PCT/IB2011/052241 WO2011148310A1 (en) | 2010-05-25 | 2011-05-23 | Method for culturing adipocytes |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2576770A1 true EP2576770A1 (en) | 2013-04-10 |
Family
ID=42938483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11727787.1A Withdrawn EP2576770A1 (en) | 2010-05-25 | 2011-05-23 | Method for culturing adipocytes |
Country Status (8)
Country | Link |
---|---|
US (1) | US20130183706A1 (en) |
EP (1) | EP2576770A1 (en) |
JP (1) | JP2013526291A (en) |
CN (1) | CN102985533A (en) |
AU (1) | AU2011259756A1 (en) |
CA (1) | CA2800667A1 (en) |
FR (1) | FR2960549B1 (en) |
WO (1) | WO2011148310A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102078602B1 (en) * | 2015-07-23 | 2020-02-19 | 한국화학연구원 | Method for 3-dimensional co-culture of adipocytes with macrophages |
US10085963B2 (en) * | 2015-11-10 | 2018-10-02 | Sami Labs Limited | Process and compositions for achieving mammalian energy balance |
CN106399234A (en) * | 2016-08-31 | 2017-02-15 | 肖锷 | Processing method of adipose tissue, mesenchymal stem cell, single processed adipose cell, and extracellular matrix |
CN107118944A (en) * | 2017-06-19 | 2017-09-01 | 方育峰 | A kind of device for improving fat cell survival rate in autologous fat DaphniaCarinat a |
WO2019093477A1 (en) * | 2017-11-10 | 2019-05-16 | 凸版印刷株式会社 | Artificial fat tissue and method for producing same, method for producing artificial skin and agent for fat cell culture |
US11774391B2 (en) | 2018-12-31 | 2023-10-03 | Water Analytics, Inc. | Grease interceptor level analyzer |
US11340096B2 (en) | 2018-12-31 | 2022-05-24 | Water Analytics, Inc. | Grease interceptor level analyzer |
US11097134B2 (en) * | 2019-05-16 | 2021-08-24 | Academia Sinica | Caveolin-1 antibody for use in treating brain inflammation and injury and improving functional recovery |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19903920B4 (en) * | 1999-02-01 | 2005-08-25 | Zouboulis, Ch.C., Priv.-Doz.Dr. | Sebocytes, sebocyte cell line and their uses |
KR20040094910A (en) * | 2002-04-03 | 2004-11-10 | 아르테셀 사이언스, 인크. | Improvements of adipocytic differentiated adipose derived adult stem cells and uses thereof |
CA2484187A1 (en) * | 2002-05-01 | 2003-11-13 | Adipogenix, Inc. | Human adipocyte cell populations and methods for identifying modulators of same |
EP1888102A4 (en) * | 2005-06-10 | 2008-10-15 | Univ Louisiana State | MODULATION OF PERIPHERAL CLOCKS IN ADIPOSE TISSUE |
GB2436837A (en) * | 2006-04-05 | 2007-10-10 | Univ Open | Culturing adipocytes |
-
2010
- 2010-05-25 FR FR1002180A patent/FR2960549B1/en not_active Expired - Fee Related
-
2011
- 2011-05-23 CN CN2011800287684A patent/CN102985533A/en active Pending
- 2011-05-23 WO PCT/IB2011/052241 patent/WO2011148310A1/en active Application Filing
- 2011-05-23 JP JP2013511773A patent/JP2013526291A/en active Pending
- 2011-05-23 EP EP11727787.1A patent/EP2576770A1/en not_active Withdrawn
- 2011-05-23 AU AU2011259756A patent/AU2011259756A1/en not_active Abandoned
- 2011-05-23 US US13/699,232 patent/US20130183706A1/en not_active Abandoned
- 2011-05-23 CA CA2800667A patent/CA2800667A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2011148310A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2800667A1 (en) | 2011-12-01 |
AU2011259756A1 (en) | 2012-12-20 |
US20130183706A1 (en) | 2013-07-18 |
FR2960549A1 (en) | 2011-12-02 |
FR2960549B1 (en) | 2015-06-19 |
WO2011148310A1 (en) | 2011-12-01 |
CN102985533A (en) | 2013-03-20 |
JP2013526291A (en) | 2013-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011148310A1 (en) | Method for culturing adipocytes | |
Kim et al. | Comparison of immunological characteristics of mesenchymal stem cells from the periodontal ligament, umbilical cord, and adipose tissue | |
EP1527161B1 (en) | Stem cells derived from adipous tissue and differentiated cells derived from said cells | |
Ahfeldt et al. | Programming human pluripotent stem cells into white and brown adipocytes | |
Karahuseyinoglu et al. | Functional structure of adipocytes differentiated from human umbilical cord stroma-derived stem cells | |
Zaba et al. | Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells | |
Ali et al. | Multi-lineage differentiation of human umbilical cord Wharton’s jelly mesenchymal stromal cells mediates changes in the expression profile of stemness markers | |
US20100015104A1 (en) | Generation of adipose tissue and adipocytes | |
FR3059009A1 (en) | CELL MICROCOMPARTMENT AND METHODS OF PREPARATION | |
EP1349919A1 (en) | Extramedullary adipose tissue cells and use thereof for regenerating hematopoietic and muscular tissues | |
US20100151574A1 (en) | Multipotent progenitor cell derived from adipose tissue | |
WO2002029010A2 (en) | Method for obtaining in vitro mammal islet cells and uses thereof | |
Sadie‐Van Gijsen | Adipocyte biology: It is time to upgrade to a new model | |
CA2509642A1 (en) | Culture medium composition, culture method, and myoblasts obtained, and their uses | |
Zhang et al. | Effects of hypoxia on proliferation and osteogenic differentiation of periodontal ligament stem cells: an in vitro and in vivo study | |
JP3762975B2 (en) | Monocyte-derived pluripotent cells MOMC | |
Bonnamain et al. | Expression of heme oxygenase-1 in neural stem/progenitor cells as a potential mechanism to evade host immune response | |
Nobusue et al. | Establishment and characteristics of porcine preadipocyte cell lines derived from mature adipocytes | |
CA2956768A1 (en) | Method for in vitro production of adipocyte progenitors and adipocytes | |
WO2012038668A1 (en) | Method for obtaining differentiated articular chondrocytes in vitro or ex vivo, and uses of same | |
Moshrefi et al. | Transplantation of differentiated umbilical cord mesenchymal cells under kidney capsule for control of type I diabetes in rat | |
FR2962443A1 (en) | ADIPOSE TISSUE MODEL AND PROCESS FOR PREPARING THE SAME | |
FR3079239A1 (en) | NOVEL METHOD OF OBTAINING T CELLS FROM PLURIPOTENT STEM CELLS AND USES THEREOF | |
JP3928881B2 (en) | Monocyte-derived pluripotent cells MOMC | |
White | Select Lipid Signaling Derived from T-cells is an Important Contributor to Type 1 Diabetes Development |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20121221 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20140227 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20160504 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20160915 |